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Abstract
A major feature of Alzheimer’s disease (AD) is the loss of noradrenergic locus coeruleus (LC) projection neurons that
mediate attention, memory, and arousal. However, the extent to which the LC projection system degenerates
during the initial stages of AD is still under investigation. To address this question, we performed tyrosine
hydroxylase (TH) immunohistochemistry and unbiased stereology of noradrenergic LC neurons in tissue harvested
postmortem from subjects who died with a clinical diagnosis of no cognitive impairment (NCI), amnestic mild
cognitive impairment (aMCI, a putative prodromal AD stage), or mild/moderate AD. Stereologic estimates of total
LC neuron number revealed a 30% loss during the transition from NCI to aMCI, with an additional 25% loss of LC
neurons in AD. Decreases in noradrenergic LC neuron number were significantly associated with worsening
antemortem global cognitive function as well as poorer performance on neuropsychological tests of episodic
memory, semantic memory, working memory, perceptual speed, and visuospatial ability. Reduced LC neuron
numbers were also associated with increased postmortem neuropathology. To examine the cellular and molecular
pathogenic processes underlying LC neurodegeneration in aMCI, we performed single population microarray
analysis. These studies revealed significant reductions in select functional classes of mRNAs regulating mitochondrial
respiration, redox homeostasis, and neuritic structural plasticity in neurons accessed from both aMCI and AD
subjects compared to NCI. Specific gene expression levels within these functional classes were also associated with
global cognitive deterioration and neuropathological burden. Taken together, these observations suggest that
noradrenergic LC cellular and molecular pathology is a prominent feature of prodromal disease that contributes to
cognitive dysfunction. Moreover, they lend support to a rational basis for targeting LC neuroprotection as a disease
modifying strategy.
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Introduction
Sporadic Alzheimer’s disease (AD) is believed to have an
extensive preclinical stage since neuropathological exami-
nations of older people with a clinical diagnosis of no or
mild cognitive impairment (MCI; a putative prodromal
stage of AD) consistently reveal similar pathological signa-
tures to those with frank AD [2, 77]. Thus, identifying
events that occur in the preclinical stages of AD will be
essential for therapeutic target identification within a
disease-modifying window. In this regard, noradrenergic
neurons of the nucleus locus coeruleus (LC) projection
system, which provide the primary source of norepineph-
rine (NE) to the forebrain, mediate memory and attention
[16, 105] and degenerate in advanced AD [19, 24, 36, 75,
86, 119], yet there is evidence for the involvement of this
system earlier in the disease process. For instance, neuro-
fibrillary tangle (NFT) deposition in the LC has been
noted in aged control and cognitively impaired subjects
and LC NFTs correlate with global cognition [55], in line
with reduced NE levels in the hippocampus and cortex in
AD [1, 75, 94]. Moreover, it has been suggested that the
* Correspondence: scott.counts@hc.msu.edu
1Department of Translational Science and Molecular Medicine, Michigan
State University, 333 Bostwick Ave NE, Grand Rapids, MI 49503, USA
2Cell and Molecular Biology Program, Michigan State University, East Lansing,
MI, USA
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Kelly et al. Acta Neuropathologica Communications  (2017) 5:8 
DOI 10.1186/s40478-017-0411-2
LC is an initial site of NFT formation in young adults and
during aging, thus serving as a potential nidus for NFT
propagation during disease progression [21, 55].
Reductions in LC neuron number are also associated
with increased cortical amyloid plaque and NFT loads
[18, 108] and correlate better with onset and duration
of AD than cholinergic nucleus basalis degeneration
[48, 76, 124]. More recently, morphometric studies
have shown that 1) the volume and number of total
neurons in the LC undergo a step-wise reduction with
successive Braak stage [110], and 2) there is a signifi-
cant loss of neuromelanin-containing LC neurons in in-
dividuals meeting the clinical pathologic criteria for
MCI [e.g., clinical dementia rating (CDR) = 0.5 with low
to intermediate AD pathology] [7]. In the present study,
we expanded on these observations by using tyrosine
hydroxylase (TH) immunohistochemistry and unbiased
stereology to investigate the extent of noradrenergic LC
neuron loss in postmortem samples obtained from
subjects who received an antemortem clinical diagno-
sis of no cognitive impairment (NCI), amnestic MCI
(aMCI; the MCI subtype most likely to convert to
frank AD [96, 121, 122]), or mild/moderate AD. TH-
immunoreactive (-ir) LC neuron numbers were evalu-
ated with respect to both antemortem neuropsycho-
logical test scores and postmortem pathological
diagnostic criteria.
While morphometric studies of LC cell loss help to de-
lineate its relative status within the spatiotemporal pat-
tern of selective neuronal vulnerability in AD [7, 108,
124], the molecular mechanisms underlying LC neuro-
degeneration during disease progression have yet to be
fully understood. To gain a better understanding of po-
tential molecular mechanisms driving LC neuronal dys-
function during the onset of AD, we combined single
neuron RNA amplification strategies with custom-
designed microarrays to analyze differential gene expres-
sion patterns of individual TH-ir LC neurons accrued
from the same NCI, aMCI, and AD cases.
Materials and methods
Subjects and clinical neuropathologic assessments
Brainstems from de-identified subjects who died with an
antemortem clinical diagnosis of NCI (n = 11), aMCI (n =
10) or mild/moderate AD (n = 8) representing both genders
were obtained from participants in the Rush Religious Or-
ders Study (RROS), a longitudinal clinical pathologic study
of aging and AD in elderly Catholic clergy [14, 87]. The
study was determined to be exempt from IRB review by the
participating institutions. Although RROS participants are
not representative of a community-based sample, the basic
neurobiological process underlying cognitive impairment in
this cohort is likely the same as in others. For instance,
neuropathological studies of MCI show similar results in
the RROS [13, 67, 88], Washington University [100], and
University of Kentucky [77] cohorts.
Table 1 summarizes the demographic, clinical, and
neuropathological characteristics of the subjects exam-
ined. Details of cognitive evaluations and diagnostic cri-
teria have been extensively published [14, 34, 87, 95].
Briefly, a team of investigators performed annual neuro-
psychological performance testing including the Mini
Mental State Exam (MMSE) and 17 additional neuro-
psychological tests referable to five cognitive domains: epi-
sodic memory (immediate and delayed recall of the East
Boston Story and Story A from Logical Memory, Word
List Memory, Word List Recall, Word List Recognition),
semantic memory (15-item Boston Naming Test, Verbal
Fluency, 15-item word reading test), working memory
(Digit Span Forward, Digit Span Backward, Digit Order-
ing), perceptual speed (Symbol Digit Modalities, Number
Comparison), and visuospatial abililty (Judgment of Line
Orientation, Standard Progressive Matrices). A Global
Cognitive Score (GCS), consisting of a composite z-score
calculated from this test battery, was determined for each
participant. A board-certified neurologist with expertise in
the evaluation of the elderly made the clinical diagnosis
based on impairments in each of the five cognitive do-
mains and a clinical examination. The diagnosis of de-
mentia or AD met recommendations by the joint working
group of the National Institute of Neurologic and Com-
municative Disorders and Stroke/AD and Related Disor-
ders Association (NINCDS/ADRDA) [79]. The aMCI
subjects exhibited impairment in episodic memory on
neuropsychological testing but did not meet the criteria
for AD or dementia. These criteria for aMCI are consist-
ent with those used by others in the field [97].
At autopsy, tissue from one hemisphere and brainstem
was immersion-fixed in a solution consisting of 4% parafor-
maldehyde in 0.1 M phosphate buffer (pH 7.2) for 24–72 h
at 4 °C followed by cryoprotection, whereas tissue from the
opposite hemisphere was frozen at −80 °C [34, 53, 88].
Series of fixed paraffin embedded tissue were prepared for
neuropathological evaluation including visualization and
quantitation of neocortical and hippocampal amyloid pla-
ques and NFTs using antibodies directed against Aβ pep-
tide (Aβ; 4G8, Covance), tau (PHF1, a gift from Dr. Peter
Davies, Hofstra Northwell School of Medicine) [14, 88], as
well as thioflavine-S histochemistry and a modified
Bielschowsky silver stain. Lewy bodies were revealed using
antibodies directed against ubiquitin and α-synuclein. Ex-
clusion criteria for cases selected for this study included
evidence of argyrophilic grain disease, frontotemporal de-
mentia, Lewy body disease, mixed dementia, Parkinson’s
disease, and stroke. A board certified neuropathologist
blinded to the clinical diagnosis performed the
neuropathological evaluation. Neuropathological cri-
teria were based on NIA-Reagan, CERAD, and
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Braak staging [20, 61, 82]. Amyloid burden and
apolipoprotein E (ApoE) genotype were determined
for each case as described previously [14, 88].
Immunohistochemistry
Fixed brainstem samples containing the dorsal pons were
cut at 40 μm-thickness on a freezing, sliding microtome
into 18 adjacent series and stored in a cryoprotectant so-
lution until processed. Sections containing the LC were
immunostained for TH to visualize noradrenergic neurons
[35, 65]. A full 1:18 series of sections was blocked in TBS/
0.25% Triton X-100/10% goat serum and incubated over-
night with rabbit TH antiserum (1:500; Millipore, Billerica,
MA). The sections were then sequentially incubated with
biotinylated goat anti-rabbit IgG and avidin-biotin com-
plex (ABC; Vector Labs, Burlingame, CA) and developed
using 3,3′-diaminobenzidine (DAB) enhanced with nickel
II sulfate to yield a blue-black reaction product (Fig. 1).
Stereological analysis of LC number
The optical disector method was used to determine the
number of TH-ir neurons in the left hemisphere of the









Age (years) at death:
Mean ± SD 82.3 ± 2.9 85.4 ± 7.2 84.8 ± 2.6 0.3a –
(Range) (77–86) (74–96) (80–88)
Number (%) of males: 6 (54%) 4 (40%) 4 (50%) 0.5b –
Years of education:
Mean ± SD 19.1 ± 2.1 17.9 ± 5.2 19.0 ± 2.7 0.9a –
(Range) (15–22) (8–23) (14–22)
Number (%) with ApoE ε4 allele: 3 (27%) 2 (20%) 3 (38%) 0.2b –
MMSE:
Mean ± SD 27.9 ± 1.5 26.3 ± 2.3 20.0 ± 4.9 0.0008a NCI > AD
(Range) (26–30) (22–30) (14–27)
Global Cognitive Score:
Mean ± SD 0.59 ± 0.3 0.02 ± 0.3 −1.0 ± 0.6 0.0002a NCI > (MCI, AD)
(Range) (−0.08–0.9) (−0.53–0.3) (−1.5– −0.2)
Post-mortem interval (hours):
Mean ± SD 4.9 ± 2.0 6.2 ± 5.2 4.0 ± 1.1 0.8a –
(Range) (2.2–8.5) (2.0–15.0) (2.7–5.8)
Distribution of Braak scores:
0 0 0 0
I/II 4 1 0 0.02a NCI < AD
III/IV 6 7 3
V/VI 1 2 5
NIA Reagan diagnosis (likelihood of AD):
No AD 0 0 0
Low 5 4 0 0.03a (NCI, MCI) < AD
Intermediate 5 4 4
High 1 2 4
CERAD diagnosis:
No AD 3 4 0
Possible 2 2 0 0.02a (NCI, MCI) < AD
Probable 4 2 3
Definite 2 2 5
aKruskal-Wallis test, with Bonferroni correction for multiple comparisons. bFisher’s exact test, with Bonferroni correction for multiple comparisons
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LC (StereoInvestigator, MicroBrightField; Williston, VT)
using an Olympus BX-60 microscope coupled to a Prior
H128 computer-controlled x-y-z motorized stage and a
high-sensitivity Hitachi 3CCD video camera system [90,
91]. Previous studies have demonstrated equivalent
neuron numbers between the left and right hemispheres
of the LC [25, 50, 93]. The region containing the LC and
subcoeruleus was outlined at 5x and disectors were
placed at 1000 μm steps along the x- and y-axis from a
random start within this reference space. The sampling
strategy was optimized using the StereoInvestigator
oversample-resample probe, such that TH-ir neurons
were counted under a 60x planar oil-immersion object-
ive (1.4 numerical aperture) in a 120 μm2 counting
frame with a 10 μm dissector height. Once the top of
the section was in focus, the z-plane was lowered 1–
2 μm. Care was taken to ensure that the top forbidden
plane was never included in the analysis. Using these pa-
rameters, at least 200 TH-ir neurons were sampled from
each series, achieving coefficients of error [56] values of
<0.10 [118]. In the present study, lightly and darkly
stained TH-ir neurons containing either a well-defined
nucleus or nucleolus were counted by a stereologist
blinded to the age, sex, cause of death, and clinical clas-
sification. Antibody penetration analysis through the full
depth of the section was performed to ensure that all
objects were counted.
LC neuronal accession and gene expression profiling
TH-labeled tissue sections processed for custom-
designed microarray analysis were prepared without
cover-slipping and maintained in RNase-free conditions
as described previously for cholinergic nucleus basalis
neurons and CA1 pyramidal neurons [27, 53, 54, 111].
Approximately 50 TH-ir LC neurons were captured per
sample and a total of 3–4 samples of LC neurons/case
were accessed by laser capture microdissection (LCM;
ArcturusXT; Applied Biosystems, Foster City, CA) and
subjected to custom-designed microarray analysis (5150
total neurons, 103 arrays total) [27, 53, 54, 111].
RNA amplification from LC neurons was performed
using terminal continuation (TC) RNA amplification
[3, 26, 52]. Briefly, microaspirated LC neurons were
homogenized in 500 μL Trizol reagent (Invitrogen,
Carlsbad, CA). RNAs were reverse transcribed in the
presence of the poly d(T) primer (100 ng/μl) and TC
primer (100 ng/μl) in 1x first strand buffer (Life Tech-
nologies, Carlsbad, CA), 2 μg of linear acrylamide (Ap-
plied Biosystems), 10 mM dNTPs, 100 μM DTT, 20 U
of SuperRNase Inhibitor (Life Technologies), and 200
U of reverse transcriptase (Superscript III, Life Tech-
nologies). Single-stranded cDNAs were digested with
RNase H and re-annealed with the primers in a ther-
mal cycler: RNase H digestion step at 37 °C, 30 min;
denaturation step 95 °C, 3 min; primer re-annealing
step 60 °C, 5 min. This step generated cDNAs with
double-stranded regions at the primer interface. Sam-
ples were purified by column filtration (Montage PCR
filters; Millipore). Hybridization probes were synthe-
sized by in vitro transcription using 33P incorporation
in 40 mM Tris (pH 7.5), 6 mM MgCl2, 10 mM NaCl,
2 mM spermidine, 10 mM DTT, 2.5 mM ATP, GTP
and CTP, 100 μM of cold UTP, 20 U of SuperRNase
Inhibitor, 2 KU of T7 RNA polymerase (Epicentre,
Madison, WI), and 120 μCi of 33P-UTP (Perkin-
Elmer, Boston, MA) [3, 27, 53] at 37 °C for 4 h. Radi-
olabeled TC RNA probes were hybridized to custom-
designed microarrays without further purification.
Arrays were hybridized overnight at 42 °C in a
rotisserie oven and washed sequentially in 2X SSC/
0.1% SDS, 1X SSC/0.1% SDS, and 0.5X SSC/0.1%
SDS for 20 min each at 42 °C. The arrays were
placed in a phosphor screen for 24 h and developed
on a Storm phosphor imager (GE Healthcare, Pis-
cataway, NJ).
Custom-designed microarray platforms and data
collection
Array platforms consisted of 1 μg linearized cDNA puri-
fied from plasmid preparations adhered to high-density
Fig. 1 LC cell loss in aMCI. a Representative TH-ir neuron and fiber staining in dorsal pontine tissue harvested from NCI, aMCI, and mild/moderate
AD subjects. b Unbiased stereological cell counts revealed a significant ~30% decrease in the number of LC neurons in aMCI compared to NCI
cases. There was a ~50% loss of LC neurons in the AD group compared to NCI. **, p < 0.01, ***, p < 0.001 compared to NCI, via one-way ANOVA
with Bonferroni post hoc testing. There was also a significant ~25% difference in neuronal cell counts between the aMCI and AD groups
(p < 0.05). me5 = mesencephalic tract of 5. Scale Bar = 100 μm
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nitrocellulose (Hybond WL, GE Healthcare) [3, 26, 52].
The array platform consisted of approximately 576
cDNAs selected to provide a broad spectrum of markers
related to pathways of interest in neurobiology (see
[111] for a list of array targets). Hybridization signal in-
tensity was determined using Image Quant software (GE
Healthcare) and quantified by subtracting background
using an empty vector (pBluescript). Expression of TC
amplified RNA bound to each linearized cDNA minus
background was expressed as a ratio of the total
hybridization signal intensity of the array (i.e., global
normalization) [27, 52]. The data analysis generated ex-
pression profiles of relative changes in mRNA levels
among the noradrenergic LC neurons dissected from
each case within the clinical diagnostic groups.
Data analysis and statistics
Demographic variables (Table 1) were compared among
clinical diagnostic groups by Kruskal-Wallis or Fisher’s
Exact tests with Bonferroni correction for pairwise com-
parisons. LC neuron number was compared across
groups by one-way ANOVA with Bonferroni post hoc
testing. Associations between LC neuron number and
clinical pathological variables were tested using Spear-
man rank correlations. Relationships found to be signifi-
cant by correlation were investigated further using linear
regression analysis. The level of statistical significance
was set at p < 0.05.
A one-way ANOVA with post hoc Newman-Keuls ana-
lysis was used to evaluate relative changes in total
hybridization signal intensity for individual mRNAs. The
level of statistical significance was set at p < 0.01. A false
discovery rate controlling procedure was used to reduce
type I errors due to the large number of genes analyzed
simultaneously [4, 26, 31, 103]. Expression levels of se-
lect mRNAs were clustered and displayed using a bio-
informatics and graphics software package (GeneLinker
Gold, Improved Outcomes, Kingston, ON). Associations
between the expression levels of select transcripts and
clinical pathological variables were tested using Spear-
man rank correlations. The level of statistical signifi-
cance was set at p < 0.05.
Results
Case demographics
Table 1 summarizes the clinical, neuropathological, and
demographic characteristics of the 29 cases examined.
Statistical analysis revealed no significant differences in
age, gender, education level, ApoE4 status, or postmor-
tem interval (PMI) across the groups examined. Cogni-
tive testing scores were available within the last year of
life. The average interval from last evaluation to time of
death was 7.2 ± 2.8 months with no significant differ-
ences among the 3 diagnostic groups (p = 0.63). The AD
subjects performed significantly worse on the MMSE
compared to the NCI cases (p = 0.0008), and GCS z-
scores were significantly decreased in aMCI and AD
compared to NCI (p = 0.0002). Braak scores were also
significantly different across the clinical groups. The
NCI cases displayed significantly lower Braak scores
than the AD group (p = 0.02). NCI cases were classified
as Braak stages I/II (36%), III/IV (54%), or V/VI (10%).
The aMCI cases met the criteria for Braak stages I/II
(10%), III/IV (70%), and V/VI (20%), and the AD cohort
was classified as either Braak stages III/IV (38%) or V/VI
(62%). The NIA-Reagan diagnosis for likelihood of AD
significantly differentiated NCI and aMCI from AD sub-
jects (p = 0.03). CERAD scores were significantly higher
in AD compared to NCI and aMCI (p = 0.02).
LC neuronal cell loss during the progression of AD
TH immunohistochemistry was used to estimate
changes in the number of noradrenergic LC neurons
across the clinical diagnostic groups (Fig. 1). Qualita-
tively, we observed a step-wise decrement in TH-ir neu-
rons within the LC from NCI to aMCI to mild/moderate
AD (Fig. 1a). Unbiased stereological cell counts validated
these observations. The estimated number of TH-ir LC
neurons in the NCI group was 19,495 ± 2,891(mean ±
SD; range = 25,867–14,758), whereas neuron number
was progressively decreased in the aMCI (14,283 ± 2,757;
range = 19,874–10,645) and AD ( 10,628 ± 2,946; range
= 15,834–6,453) groups. Statistical comparisons revealed
a significant ~30% decrease in the number of LC neu-
rons in aMCI compared to NCI cases (p < 0.01) (Fig. 1b).
An additional ~25% decrease in LC neuron number was
quantified in AD compared to aMCI (p < 0.05), resulting
in a ~45–50% loss of LC neurons in the AD group com-
pared to NCI (p < 0.001) (Fig. 1b). Total LC neuron
number was similar between males and females in each
diagnostic group (data not shown).
Clinical pathologic correlations
Estimated TH-ir LC neuronal counts were correlated
with demographic data, antemortem cognitive test per-
formance, and postmortem neuropathologic variables.
Neuron number was not associated with age (r = −0.18,
p = 0.3) or PMI (r = 0.07, p = 0.5). There were no associa-
tions between neuron number and gender or ApoE sta-
tus (data not shown). However, there was a strong
association between reduction in LC neuron number
and decline in cognitive status. For instance, lower LC
neuron numbers and MMSE scores displayed a signifi-
cant positive association (r = 0.61, p < 0.001). Moreover,
TH-ir LC neuron number was significantly associated
with individual GCS, the composite z-score of the 17
neuropsychological tests administered prior to death (r
= 0.7, p < 0.0001) (Fig. 2), as well as with the final
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composite scores referable to episodic memory (r = 0.71,
p < 0.0001), sematic memory (r = 0.58, p = 0.0008), work-
ing memory (r = 0.6, p = 0.0006), perceptual speed (r =
0.66, p < 0.0001), and visuospatial ability (r = 0.53, p =
0.003; Fig. 2) [14]. Notably, most of these positive associ-
ations between LC neuron numbers and cognitive test
scores remained significant even when the NCI and
aMCI groups alone were analyzed (Table 2). With re-
spect to neuropathological diagnostic criteria, reductions
in TH-ir LC neuron numbers were negatively correlated
with increasing measures of neuropathology as charac-
terized by Braak (r = −0.46, p = 0.01), NIA-Reagan (r =
−0.45, p = 0.01), and CERAD (r = −0.41, p = 0.03) staging
(Fig. 2). Finally, regression modeling revealed that only
GCS (p = 0.004), but not Braak (p = 0.49), NIA-Reagan
(p = 0.81), or CERAD (p = 0.28) score, served as a pre-
dictor for the number of TH-ir LC neurons.
Dysregulation of LC neuronal gene expression in MCI and
AD
To identify potential molecular pathogenic alterations
underlying LC cell loss observed during AD progression,
we performed custom-designed microarray analysis using
mRNA extracted from individual TH-ir LC neurons
accessed from the NCI, aMCI and mild/moderate AD
cases. LC neurons displayed a significant downregulation
of transcripts regulating mitochondrial function in aMCI
and AD compared to NCI subjects (Fig. 3a, b). Significant
downregulation was observed for select genes regulating
respiration, including cytochrome C1 (Cytc1; 50%; p <
0.01) and nuclear respiratory factor 1(Nrf1; 45%; p < 0.01),
as well as redox gene expression, including superoxide
dismutase 2 (Sod2; 50%; p < 0.01) and glutathione peroxid-
ase 1 (Gpx1; 55%; p < 0.001). By contrast, significant up-
regulation in the expression of the phosphofructokinase-
liver (Pfkl; 50%; p < 0.01) and phosphofructokinase-platelet
(Pfkp; 50%; p < 0.01) isozymes were detected in LC
Fig. 2 TH-ir LC neuron number correlates with multiple measures of antemortem cognition and postmortem neuropathology during the
progression of AD. Scatterplots show significant relationships between reductions in LC neurons and a the GCS for each individual (r = 0.7, p <
0.0001), as well as poorer performance on composite scores of b episodic memory (r = 0.71, p < 0.0001), c semantic memory (r = 0.598, p =
0.0008), d working memory (r = 0.6, p = 0.0006), e perceptual speed (r = 0.66, p < 0.0001), and f visuospatial ability (r = 0.53, p = 0.003). There were
also significant negative correlations between TH+ neuron number and increasing neuropathology as defined by g Braak (r = −0.46, p = 0.01), h
CERAD (r = −0.41, p = 0.03), and i NIA-Reagan (r = −0.45, p = 0.01) diagnostic criteria. All associations were tested using Spearman rank correlation
analysis. Abbreviations: TH+ (TH-positive), POSS. (possible), PROB. (probable), DEF. (definite), INT. (intermediate). Symbols: NCI (blue-filled circle),
aMCI (green-filled circle), AD (red-filled circle)
Table 2 Correlations between neuron number and cognitive
test scores: NCI and aMCI subjects only
MMSE r = 0.46 (p = 0.03)
GCS r = 0.58 (p = 0.006)
episodic memory r = 0.55 (p = 0.01)
semantic memory r = 0.29 (p = 0.2)
working memory r = 0.6 (p = 0.004)
perceptual speed r = 0.51 (p = 0.02)
visuospatial ability r = 0.55 (p = 0.009)
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neurons from AD subjects relative to NCI and aMCI
(Fig. 3a, b).
Gene expression analysis also revealed a significant
downregulation of transcripts related to neuritic/structural
plasticity in cases with an antemortem clinical diagnosis of
aMCI and AD compared to NCI, including mRNAs encod-
ing microtubule associated binding protein 1b (Map1b;
50%; p < 0.01), neurofilament heavy chain (Nfh; 65%; p <
0.001), cell surface adhesion molecule integrin alpha 3 sub-
unit (Itga3; 55%; p < 0.001), axon guidance protein netrin
(Ntn1; 40%; p < 0.01), postsynaptic clustering protein utro-
phin (Utrn; 45%; p < 0.01), and the dendritic spine plasticity
protein synaptopodin (Synpo; 60%; p < 0.01) (Fig. 3a, c).
Moreover, an analysis of transcripts encoding the six tau
isoforms (Mapt1-Mapt6) [54] revealed a significant ~25–
30% decrease in the ratio of 3-repeat tau (3Rtau) to 4-
repeat tau (4Rtau) isoform expression within single LC neu-
rons in aMCI and AD compared to NCI cases (Table 3). In
contrast, an upregulation of the cytoskeletal proteases
calpain 1 (Capn1; 45%; p < 0.01) and calpain 2 (Capn2;
55%; p < 0.01) was found in AD (Fig. 3c).
Several transcripts encoding other functional classes of
genes relevant to AD pathogenesis were unaffected. For
example, levels of amyloid-β precursor protein (App) and
several genes related to APP metabolism, such as beta-site
APP-cleaving enzyme 1 (Bace1), presenilin 1 (Psen1), and
APP family member genes amyloid precursor-like protein
1 (Aplp1) and amyloid precursor-like protein 2 (Aplp2)
were not differentially regulated in LC neurons across the
clinical groups (Additional file 1: Figure S1).
Correlations with clinical pathologic variables
Although there were no associations between transcript
levels and age or PMI, there was a strong relationship
Fig. 3 Single LC neuron expression profiling reveals alterations in mRNAs regulating mitochondrial and neuritic function during AD progression. a
Primary custom microarray data showing hybridization signal intensities of select mRNA transcripts within TH-ir LC neurons in NCI and aMCI.
Abbreviations: cytochrome C1 (Cytc1), glutathione peroxidase (Gpx1), glucose transporter 3 (Glut3), phosphofructokinase-liver isozyme (Pfkl),
microtubule associated binding protein 1a (Map1a), and neurofilament heavy (Nfh), medium (Nfm), or light (Nfl) chain subunits. b Heatmap
shows significant decreases in transcripts regulating mitochondrial fucntion in LC neurons in aMCI and AD cases compared to NCI, including Cytc1,
nuclear respiratory factor 1 (Nrf1), superoxide dismutase 2 (Sod2) and Gpx1, whereas Pfkl and platelet (Pfkp) isozymes were up-regulated in mild AD (red
to green = decreasing expression levels). Additional abbreviations: superoxide dismutase 1 (Sod1), glutathione transferase (Gst), cytochrome p450 11a
(Cyp11a), and pfk-muscle (Pfkm). c Heatmap shows significant decreases in transcripts regulating cytoskeletal/structural plasticity in LC neurons in aMCI
and AD cases compared to NCI, including Map1b, Nfh, integrin 3 (Itga3), netrin 1 (Ntn1), utrophin (Utrn), and synaptopodin (Synpo), whereas calpain 1
(Capn1, m-calpain) and calpain 2 (Capn2, μ-calpain) were up-regulated in mild AD (red to green = decreasing expression levels). Additional mRNAs:
mitochondrial associated protein 2 (Map2), and synaptojanin (Synj). a, NCI > aMCI, AD, p < 0.01; b, NCI > aMCI, AD, p < 0.001; c, AD > NCI,
aMCI, p < 0.01
Table 3 3Rtau/4Rtau mRNA ratios in single LC neurons






NCI 1.36 ± 0.11 1.12 ± 0.14 1.25 ± 0.07
aMCI 1.02 ± 0.09* 0.81 ± 0.08* 0.92 ± 0.12*
AD 0.98 ± 0.1* 0.83 ± 0.05* 0.89 ± 0.13*
* p < 0.05 via one-way ANOVA with Bonferroni correction
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between downregulation of LC metabolic and structural
plasticity gene expression and decreased GCS perform-
ance (Fig. 4) [14]. The four strongest associations were
between GCS and Cytc1 (p < 0.0001, Fig. 4a), Nrf1 (p =
0.0003, Fig. 4b), Map1b (p = 0.0006, Fig. 4c) and Synpo
(p < 0.0001, Fig. 4d) transcripts. There were also signifi-
cant associations between metabolic and structural plas-
ticity gene expression and MMSE scores (Table 4). By
comparison, stable levels of superoxide dismutase 1
(Sod1; Fig. 3b) were not associated with GCS or MMSE
scores across diagnostic groups. Virtually all of these se-
lect transcript reductions correlated negatively with in-
creasing measures of neuropathology (Braak, NIA-
Reagan, and CERAD diagnostic criteria; Table 4).
Microarray validation
Since all brainstem tissue containing the LC from the
RROS cohort is immersion-fixed [106, 120], qPCR and
immunoblot validation analyses of frozen tissue samples
were not conducted as previously described [4, 27, 53].
However, changes associated with the noradrenergic
phenotype at the single neuron level would likely be
masked by regional expression patterns from admixed
neuronal and non-neuronal cell types included in the
frozen samples required for these analyses, similar to
our observations in cholinergic neurons in the nucleus
basalis/substantia innominata [28, 30, 54]. On the other
hand, studies using regional gene expression analysis or
neuronal immunohistochemical analysis in vulnerable
brain regions have reported findings that support our
LCM-based custom microarray approach. For instance,
Map1b gene expression was downregulated in AD tem-
poral cortex [123], whereas downregulation of Synpo
protein in dendritic spines occurred in frontal cortex
neurons in AD [9] similar to that found in our LC gene
array experiments. Future studies employing single
population RNA-sequencing, Fluidigm, and/or Nano-
string nCounter analyses are warranted when transcrip-
tomic technologies become more standardized and
economical [22, 66, 73].
Discussion
We demonstrate in this report that TH-ir, presumably
noradrenergic LC neurons are vulnerable during the
onset of dementia as evidenced by their loss in aMCI
and AD and the association of this loss with multiple
measures of cognitive deterioration and neuropatho-
logical accumulation. We further characterized the
molecular underpinnings of LC neuronal vulnerability
by single population microarray analysis. Results indi-
cated selective changes in genes regulating mitochon-
drial function and neuritic/structural plasticity, which
also correlated with antemortem cognitive status and
postmortem plaque and tangle burden. Hence, the
Fig. 4 Alterations in select transcripts isolated from noradrenergic LC neurons correlate with global cognition during the progression of AD.
Scatterplots show significant relationships between decreasing levels of a Cytc1 (r = 0.64, p < 0.0001), b Nrf1 (r = 0.57, p = 0.0003), c Map1b (r = 0.59,
p = 0.0006), and d Synpo (r = 0.65, p < 0.0001) and worsening GCS score, via Spearman rank correlation analysis. Symbols: NCI (blue-filled circle),
aMCI (green-filled circle), AD (red-filled circle)
Kelly et al. Acta Neuropathologica Communications  (2017) 5:8 Page 8 of 14
early loss of forebrain monoaminergic signaling medi-
ated by the LC appears to be central to AD
pathophysiology.
Rodent and non-human primate investigations have
revealed the importance of the ascending noradrenergic
LC projection system for cognitive function [11, 16, 85].
Based on a series of seminal experiments, Aston-Jones
and Cohen proposed a theory of ‘adaptive gain’ whereby
NE integrates sensory, attentional and memory process-
ing by positively modulating signal gain in neurons to fa-
cilitate the processing of salient events by driving LC
phasic activity in response to relevant stimuli [11]. LC
bursts and pulsatile NE efflux in coeruleus target fields
(e.g., hippocampus and prefrontal cortex) increases the
activity of excitatory inputs and decreases the action of
inhibitory inputs, which optimizes task performance [11,
16]. Despite the more caudal location of the LC deep
within the brainstem it might be envisioned as the
brain’s “watchtower,” scanning incoming sensory infor-
mation for important events that require immediate at-
tention [33]. Moreover, NE-dependent modulation of
long-term alterations in synaptic strength and gene tran-
scription, particularly within the hippocampus and pre-
frontal cortex, influences memory formation and
experience-dependent alterations in neural function and
behavior and plays a critical role in the ability of the LC
to optimize performance [105]. Finally, evidence from
transgenic mouse models of AD and neuronal cell cul-
ture studies show that NE exerts a wide array of neuro-
protective effects including anti-inflammatory and pro-
neurotrophic mechanisms [32, 43, 44, 58, 64, 72, 74,
117]. Taken together, these data suggest that the central
NE projection system is essential for cognitive function
and, in turn, that LC neuronal degeneration contributes
to cognitive dysfunction.
Recently, two reports have shown that LC neurode-
generation coincides with both mounting Braak stage
pathology [110] and cognitive impairment [7]. Theofilas
and colleagues reported that LC volume decreases
~8.4% with each successive Braak stage, resulting in a
significant ~25% loss of LC volume between control
cases neuropathologically diagnosed postmortem as
Braak stage III compared to stage 0 [110]. This volume
loss mirrored a similar rate of change in total pigmented
and non-pigmented LC neuron numbers, as measured
by unbiased stereology [110]. The authors also noted
that the topography of LC volume and cell loss appears
to follow a rostrocaudal gradient similar to that reported
in frank AD cases [49, 110]. Here, we report that the loss
of TH-ir, presumably noradrenergic LC neurons also
correlates with Braak stage. In addition, we found that
TH-ir neuron loss correlated with increasing neuropath-
ologic burden based on NIA-Reagan and CERAD diag-
nostic criteria. As reductions in LC neuron number have
been associated with increased cortical amyloid plaque
and NFT loads in cases of frank AD [18, 108], these ob-
servations in early stage cases indicate a strong relation-
ship between LC projection system degeneration and the
pathologic sequela of AD.
Arendt and colleagues used unbiased stereology to
demonstrate a significant ~13% loss of neuromelanin-
positive LC neurons in subjects classified as MCI/pro-
dromal AD (CDR 0.5 who also displayed “low” to “inter-
mediate” amyloid-Braak-CERAD (ABC) diagnostic
scores [61]) compared to those classified as controls
(CDR 0 and “not” ABC score) [7]. Subjects classified as
mild/moderate AD exhibited ~30–45% LC cell loss com-
pared to controls. This study revealed that LC cell loss,
which is prominent in cases of frank AD [19, 24, 36, 75,
86, 119], appears to occur early in the clinical progres-
sion of AD, concurrent with cell loss in the nucleus
basalis and entorhinal cortex [7].
The present morphometric analysis revealed a ~30%
loss of TH-ir LC number during the transition from
NCI to aMCI in cases classified independent of
neuropathological diagnosis. Notably, our estimate of
total TH-ir LC cell number in NCI/healthy controls
(19,495 ± 2,891) was similar to other studies [23, 50,
93, 112] and, more specifically, to Arendt and col-
leagues’ unbiased estimate of total neuromelanin-
positive neurons (17, 487 ± 2,736) for this group. The
discrepancy in the observed loss of LC neurons
Table 4 Clinical pathologic correlations of select LC neuronal transcripts dysregulated in aMCI and AD
transcript GCS MMSE Braak NIA-Reagan CERAD
cytc1 r = 0.64 (p < 0.0001) r = 0.48 (p = 0.003) r = −0.50 (p = 0.003) r = −0.41 (p = 0.02) r = −0.48 (p = 0.01)
nrf1 r = 0.57 (p = 0.0003) r = 0.37 (p = 0.04) r = −0.43 (p = 0.08) r = −0.39 (p = 0.06) r = −0.50 (p = 0.003)
gpx1 r = 0.54 (p = 0.008) r = 0.44 (p = 0.008) r = −0.42 (p = 0.02) r = −0.42 (p = 0.01) r = −0.39 (p = 0.02)
map1b r = 0.59 (p = 0.0006) r = 0.35 (p = 0.03) r = −0.43 (p = 0.01) r = −0.33 (p = 0.2) r = −0.32 (p = 0.09)
nf-h r = 0.54 (p = 0.0007) r = 0.51 (p = 0.001) r = −0.55 (p < 0.001) r = −0.49 (p = 0.005) r = −0.45 (p = 0.006)
ntn1 r = 0.52 (p = 0.0008) r = 0.44 (p = 0.007) r = −0.41 (p < 0.01) r = −0.40 (p = 0.02) r = −0.47 (p = 0.006)
synpo r = 0.65 (p < 0.0001) r = 0.52 (p < 0.001) r = −0.58 (p < 0.001) r = −0.47 (p = 0.008) r = −0.45 (p = 0.005)
sod1 r = 0.22 (p = 0.1) r = −0.11 (p = 0.5) r = −0.18 (p = 0.6) r = −0.09 (p = 0.6) r = −0.28 (p = 0.1)
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between control and MCI/prodromal AD between
these two studies (~30% compared to ~13%) could be
related to cohort group classifications or possibly to a
relatively greater loss of TH-expressing neurons com-
pared to neuromelanin-positive neurons early in the
disease process. In this regard, it would be interesting
to determine whether a subset of neuromelanin-
positive LC neurons undergoes a phenotypic down-
regulation of TH during the disease. Regardless, the
present findings suggest that a disconnection of
transmitter-identified LC projections to the forebrain
contributes to the presentation of clinical disease.
With respect to the relationship between LC degener-
ation and cognitive status across the diagnostic groups,
we found that reduced numbers of TH-ir LC neurons
were associated not only with episodic memory deficits
that define aMCI subtypes [63], but also with semantic
memory, working memory, perceptual speed, and visuo-
spatial ability. Since the LC innervates components of
the dorsal memory network (e.g., dorsolateral and dor-
somedial prefrontal cortex) [10, 84] and the amygdala
[46, 99, 115], which are both dysfunctional early in the
onset of AD [89], disruption of NE afferents to these
structures may play a role in the deficits seen in these
various cognitive domains [14]. In fact, we found that
quantitative decreases in LC neuron number were asso-
ciated with poorer performance on measures of global
cognitive function, as well. Hence, we demonstrate a link
between loss of noradrenergic tone, neuropathological
criteria, and cognitive decline. However, regression ana-
lysis revealed that global cognitive decline, but not
neuropathological status, was a predictor for LC cell
number. These findings lend support to a previous aut-
opsy study, which showed that higher LC neuronal dens-
ity was associated with slower rates of antemortem
cognitive decline, suggesting a role for the LC in cogni-
tive reserve [120]. Altogether, our data supports an
emerging theory that LC neuron degeneration is an early
pathological event that contributes to cognitive dysfunc-
tion and the onset of AD, and is likely a site for thera-
peutic intervention.
The cellular and molecular mechanisms underlying
LC selective vulnerability in the early stages of AD are
unclear. To begin to address this question, we profiled
gene expression patterns of transmitter-identified LC
neurons microdissected from NCI, aMCI, and AD
cases. We noted two major patterns of expression
changes related to functional classes of genes regulating
mitochondrial function and neuritic plasticity. With re-
spect to the transcripts involved in mitochondrial dys-
function, Nrf1 and Cytc1 mRNA levels were both
significantly downregulated in LC neurons in aMCI and
mild AD relative to NCI. Nrf1 is a transcription factor
that directs the expression of several functional classes
of genes involved in mitochondrial function, including
those regulating redox homeostasis, mitochondrial bio-
genesis, calcium homeostasis, and cytochrome oxidase
activity [17, 40, 41]. Interestingly, Cytc1 is the heme-
containing component in the cytochrome b-c1 complex
III of the respiratory chain, accepting electrons from
Rieske protein and transferring it to cytochrome c,
which couples to cytochrome oxidase [47, 113]. By con-
trast, transcript levels of Pfkl and Pfkp isozymes were
significantly upregulated in LC neurons in AD. These
enzyme subunits catalyze the conversion of D-fructose
6-phosphate to D-fructose 1,6-bisphosphate, resulting
in the first committing step of glycolysis [60]. Taken to-
gether, these results indicate that LC neurons are under
considerable respiratory stress during the transition
from NCI to prodromal and frank AD. In addition,
these neurons displayed significant decreases in tran-
scripts encoding the antioxidant enzymes mitochon-
drial Sod2 and Gpx1 in aMCI. Given the role of these
two enzymes in detoxifying superoxide and hydrogen
peroxide, respectively, LC neurons are also likely under
considerable oxidative stress prior to the onset of aMCI
[109]. These observations support tissue-based assess-
ments demonstrating regional mitochondrial deficits
during the progression of AD [12, 15, 59, 71, 101, 102,
116, 125], but importantly, identify these changes in
neurons, as opposed to glial cells or admixed popula-
tions of cells, thus attributing these markers for mito-
chondrial dysfunction to LC neurons.
A second common thread of transcript dysregulation
in aMCI centered on genes encoding proteins involved
in axonal function and neuronal morphological plasti-
city. For instance, Map1b is critical for microtubule
stabilization during axonal growth [114] and Ntn1 plays
a role in axonal guidance [81], whereas Nfh is essential
in maintaining axonal caliber and is dysregulated in hu-
man AD and animal models of the disease [42, 83]. Sig-
nificant downregulation of these genes suggest that LC
neurons may be undergoing an axonal degenerative
process during prodromal stages, which progress to
frank AD as evidenced by a significant increase in the
cytoskeletal proteases Capn1 and Capn2 expression in
AD neurons [92, 104]. Moreover, we found a global de-
crease in the ratio of 3R/4R tau isoforms in LC neurons
in aMCI and AD, consistent with previous single cell
gene expression studies of cholinergic nucleus basalis
and CA1 pyramidal neurons isolated from MCI and AD
cases [54]. The alteration in 3R tau gene dosage relative
to 4R tau suggests a shift toward tau isoforms associated
with slower axonal transport kinetics as well as NFT for-
mation [37, 69, 107].
Finally, we observed a concomitant downregulation of
genes encoding the postsynaptic receptor clustering protein
Utrn and the dendritic spine marker Synpo in aMCI and
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AD neurons compared to NCI. In particular, Synpo is an
actin-associated protein that may play a role in modulating
actin-based shape and motility of dendritic spines and
seems to be essential for the formation of spine apparatuses
involved in synaptic plasticity [39, 68]. Dysregulation of
postsynaptic gene expression in vulnerable LC neurons
may signal perturbations prior to the onset of aMCI that
are indicative of a failure in neuroplastic and/or remodeling
programs [38, 39, 68, 89]. While we cannot rule out the
possibility that these molecular changes are epiphenomenal
to AD pathogenesis, the timing of these changes to stages
prior to the onset of aMCI suggest that they represent path-
ways critical to disease progression.
Perhaps the most striking feature of the LC is the im-
mensity and divergence of its noradrenergic forebrain
efferents [45], extensive complex dendritic arborization
pattern, and the long distance these perikarya project
to reach their forebrain innervation sites [6, 8, 85]. In
this regard, LC neurons are similar to other selectively
vulnerable long forebrain projection neuron systems
(e.g., cholinergic basal forebrain neurons, substantia
nigra pars compacta neurons, and dorsal raphe neu-
rons, among others [5, 16, 78, 80, 105]), that are heavily
reliant on energy metabolism and cytoskeletal integrity
to modulate synaptic input. These long projection sys-
tems are likely more prone to cellular stress given their
position in the brain’s organization. Taken together, our
findings present evidence for the molecular dysregula-
tion of mitochondrial function and neuritic/structural
plasticity coinciding with the loss of LC neurons prior
to the transition from NCI to prodromal AD. Moreover,
our observation that the dysregulation of these genes
correlates with poorer global cognition and greater
neuropathological burden suggests that these molecular
pathways represent pathogenic mechanisms underlying
the selective vulnerability of LC neurons which may be
common to other vulnerable neurons. Notably, there is
evidence from similar single neuron expression analysis
studies showing alterations in mitochondrial and struc-
tural plasticity pathways in AD. For instance, we have
demonstrated that cholinergic nucleus basalis neurons
exhibit alterations in Sod2, Pfkl, and Capn1 in AD [29].
Other studies have also demonstrated an AD-related
dysregulation of specific respiratory chain genes (e.g.,
cytochrome oxidase 5b) in medial temporal and poster-
ior cingulate pyramidal neurons [70, 71]. However, the
extent to which dysregulation of these pathways are
evident in other selectively vulnerable cell groups during
the onset of cognitive decline warrants further compara-
tive assessments of these neuron groups as well as rela-
tively unaffected populations in postmortem brain tissues.
Moreover, whether dysregulation of these pathways is re-
lated to NFT or Lewy body pathology in these neurons is
an additional question to be addressed in future studies
[51, 55, 62, 111, 112]. The current findings also suggest
the need for additional quantitative biochemical and im-
munohistochemical assessments of these mitochondrial
and structural markers in LC neurons in aMCI.
Conclusions
The present findings point to the continuing need to
consider noradrenergic system pathophysiology as a key
and early component associated with the progression of
AD. We posit that strategies aimed at LC neuroprotec-
tion or NE replacement are viable therapeutic options
[98]. Moreover, as prominent LC degeneration is also evi-
dent in cases of Parkinson’s disease with dementia and de-
mentia with Lewy bodies [57], maintaining LC projection
system integrity may provide a common therapeutic
mechanism for combating cognitive decline in multiple
late-onset dementia subtypes. Here, we present several
candidate molecular pathways that are dysregulated in LC
neurons early in the cascade of pathogenic events prior to
the onset of AD, which may form the basis for novel neu-
roprotective approaches for dementia.
Additional file
Additional file 1: Figure S1. No change in AD-related gene expression in
LC neurons during disease progression. Bar graph shows changes in App, Bace1,
Psen1, Aplp1, and Aplp2 transcripts in aMCI and AD relative to NCI. No significant
differences were calculated across the diagnostic groups. (TIF 998 kb)
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